OpenMed

Cover Block

PUBLIC

Attribute	Value
Name	OpenMed
Tagline	A B2B digital marketplace for pharmaceutical distribution in Latin America, connecting labs and independent pharmacies.
Headquarters	Lima, Peru
Founded	2022
Business Model	Marketplace
Industry	Logistics / Supply Chain
Technology	Software (Non-AI)
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)

Links

PUBLIC

• Website: https://openmed.com.vn/
• LinkedIn: https://www.linkedin.com/company/openmed

Executive Summary

PUBLIC

OpenMed is building a digital B2B marketplace to modernize pharmaceutical distribution in Latin America, a region where fragmented supply chains and a large base of independent pharmacies present a clear opportunity for software-driven consolidation [Infomercado, April 2023]. Founded in 2022 by a team of five, including CEO Angelo Vásquez and CTO Harold Gutiérrez, the company has launched a mobile application for pharmacies featuring a catalog of more than 2,500 products, aiming to reduce procurement time and operational costs [Infomercado, April 2023]. Its wedge is an end-to-end digital channel that connects laboratories directly with independent pharmacies, a model that seeks to bypass traditional, less efficient distribution layers. The founding team combines product, technical, and user experience roles, though their prior operational track records in scaling marketplaces or pharmaceutical logistics are not detailed in public sources. No external funding rounds or institutional investors have been publicly disclosed, suggesting the company may be in a pre-seed or bootstrapped phase. Over the next 12-18 months, the key signals to watch will be the announcement of a first institutional round, the expansion of its product catalog and pharmacy network beyond initial launch metrics, and any formal partnerships with regional pharmaceutical laboratories.

Data Accuracy: YELLOW -- Core product claims and team composition are confirmed by a single regional publisher; funding, traction metrics, and competitive positioning lack independent corroboration.

Taxonomy Snapshot

Axis	Classification
Business Model	Marketplace
Industry / Vertical	Logistics / Supply Chain
Technology Type	Software (Non-AI)
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)

Company Overview

PUBLIC

OpenMed was founded in 2022 in Lima, Peru, with the stated aim of modernizing the pharmaceutical supply chain for independent pharmacies across Latin America [Infomercado, April 2023]. The company operates as a B2B digital marketplace, a structure designed to connect laboratories directly with smaller retail pharmacies, bypassing traditional, often fragmented, distribution layers.

A key early milestone was the launch of its mobile application, which provided independent pharmacies with digital access to a catalog of more than 2,500 pharmaceutical products [Infomercado, April 2023]. The company's public narrative emphasizes an end-to-end solution intended to reduce procurement time, capital requirements, and operational workload for its pharmacy customers [Infomercado, April 2023].

The founding team includes five co-founders, with Angelo Vásquez serving as CEO, Harold Gutiérrez as CTO, Renzo Rosas as CPO, Karina Flores as Head of UX/UI, and Julio Kauss also listed as a co-founder [Infomercado, April 2023] [Infomercado]. Public records do not detail a prior corporate history, acquisitions, or significant funding events for this specific Peruvian entity, distinguishing it from other companies sharing the OpenMed name.

Data Accuracy: YELLOW -- Core company description and founding details are confirmed by a single regional press article. Team composition is corroborated across multiple sources, but other corporate milestones and legal details are not independently verified.

Product and Technology

MIXED

OpenMed’s core product is a 100% digital B2B marketplace designed to streamline pharmaceutical procurement for independent pharmacies in Latin America [Infomercado, April 2023]. The platform, which includes a mobile app, provides a digital channel for pharmacies to access a catalog of more than 2,500 products directly from laboratories, aiming to reduce the time, capital, and operational work associated with traditional distribution [Infomercado, April 2023]. The company describes this as an end-to-end solution, with data on the platform continuously reviewed and verified by health professionals [OpenMed - made with Wegic].

Key product features center on user experience and trust. The mobile app and platform are noted for an intuitive design and user-friendly features intended to simplify ordering for pharmacy staff [OpenMed - made with Wegic]. The emphasis on data verification by professionals and a commitment to secure, fairly priced delivery service suggests a focus on building reliability in a region where supply chain integrity is a critical concern [OpenMed - made with Wegic] [Emprendedores de Hoy México].

PUBLIC

The digital transformation of Latin America's fragmented pharmaceutical supply chain represents a significant, under-penetrated opportunity for efficiency gains, driven by a confluence of demographic pressure and infrastructural gaps.

Market sizing for the specific B2B pharmaceutical distribution segment in Latin America is not directly cited. The company's own material references a broader consumer market of more than 662 million people in the region and an ambition to serve more than 150 million people with chronic diseases [Infomercado, April 2023][Openmed.pe]. For context, the global pharmaceutical logistics market was valued at approximately $105 billion in 2023, with Latin America representing a high-growth region, according to analogous third-party reports [LogisticsIQ]. The serviceable addressable market for a digital marketplace connecting labs and independent pharmacies is a narrower slice of this figure, concentrated in countries with dense networks of small, owner-operated pharmacies.

Demand tailwinds are structural. The region's high prevalence of chronic diseases creates consistent, recurring demand for medication, while fragmented retail pharmacy networks,often dominated by independents rather than large chains,struggle with procurement inefficiencies. These pharmacies typically lack the purchasing power and logistical sophistication of larger counterparts, making a consolidated digital channel for inventory and delivery an attractive proposition. The push for modernization is further accelerated by broader regional digitization trends in commerce and payments, setting expectations for B2B transactions.

Key adjacent markets include direct-to-consumer pharmacy delivery and telehealth platforms, which represent both potential partners and long-term substitutes. A regulatory force is the stringent oversight of pharmaceutical distribution, which varies by country but generally requires verified suppliers and controlled logistics, potentially acting as a barrier to entry that benefits compliant, early-mover platforms. Macroeconomic volatility in some Latam currencies could also influence pharmacy inventory purchasing behavior, though a platform offering price transparency and reliable supply may be viewed as a hedge against local scarcity.

Total Latam Consumer Market | 662 | million people
Target Chronic Disease Population | 150 | million people

The cited figures, while broad, underscore the scale of the underlying need. The jump from a general consumer population to a targeted chronic disease cohort suggests the company is initially focusing on a high-frequency, predictable segment of pharmaceutical demand, which is a rational wedge for a new marketplace.

Data Accuracy: YELLOW -- Market size figures are company-stated ambitions; the 662 million consumer figure is attributed to a regional press article. No independent third-party sizing for the specific B2B pharma distribution niche in Latam is provided.

Competitive Landscape

MIXED OpenMed's competitive position is defined by its narrow focus on digitizing the fragmented, independent pharmacy supply chain in Latin America, a segment often underserved by large-scale distributors.

This limits direct comparison but provides a starting point for mapping the broader landscape.

OpenMed | 2500 | products

The company's primary competitive surface is its catalog depth, which it reports at over 2,500 pharmaceutical products [Infomercado, April 2023]. This metric is a direct proxy for its ability to serve as a one-stop procurement channel for a pharmacy owner.

• Direct digital challengers. The most immediate rivals are other B2B marketplaces targeting the same pharmacy segment in the region. These platforms compete on catalog breadth, delivery logistics, and pricing. Without further details on Farmalisto, it is difficult to assess the relative scale or operational maturity of these challengers.
• Traditional wholesale incumbents. The dominant competitive force is the established network of pharmaceutical wholesalers and distributors. These incumbents hold long-standing relationships, physical warehousing, and often offer credit terms. OpenMed's wedge is not to replace them entirely but to offer a more efficient, digital-first ordering layer that reduces the operational burden for small pharmacies.
• Adjacent substitutes. Large pharmacy chains with their own centralized procurement and digital systems represent both a potential customer segment (if they source for franchisees) and a competitive threat, as they could develop similar internal platforms. Additionally, generic e-commerce platforms could theoretically expand into pharmaceutical B2B, though they would face significant regulatory and trust barriers.

OpenMed's current defensible edge appears to be its early focus on the independent pharmacy user experience and its claimed data verification by health professionals [OpenMed - made with Wegic]. This combination of a specialized mobile interface and a layer of product curation could build loyalty among a customer base that values simplicity and reliability. However, this edge is perishable. It relies on maintaining a superior product catalog and user experience, both of which are replicable by better-funded competitors. The company's lack of publicly disclosed funding or institutional investors suggests its capital advantage, if any, is limited.

The company is most exposed on two fronts. First, it faces execution risk from incumbents who could digitize their own operations, leveraging existing customer relationships and distribution networks to launch competing services. Second, it is vulnerable to a well-funded, regional marketplace player that could enter the pharmaceutical vertical, using capital to rapidly acquire supply and undercut on price or delivery speed. OpenMed's current geographic focus on Peru provides a protective moat of local knowledge, but also limits its total addressable market.

The most plausible 18-month competitive scenario hinges on market validation and capital. If OpenMed can demonstrate strong adoption and unit economics among independent pharmacies in Peru, it becomes an attractive acquisition target for a larger distributor seeking a digital channel or a regional marketplace expanding its verticals. In this scenario, OpenMed could be the "winner" if it proves the model's viability before scaling constraints hit. Conversely, if a competitor with deeper pockets validates the model first and begins a regional land grab, OpenMed could become the "loser," squeezed out of key markets or forced into a subscale niche. The lack of public funding news makes this capital race a critical, unanswered variable.

Data Accuracy: YELLOW -- Single source for core product metric; competitor identification is minimal and unverified.

Opportunity

PUBLIC

If OpenMed can capture a meaningful share of the fragmented, inefficient pharmaceutical distribution network in Latin America, the prize is a multi-billion dollar platform business connecting a vast, underserved market.

The headline opportunity is to become the default digital procurement and logistics backbone for independent pharmacies across Peru and, eventually, the Andean region. The company's early positioning as a 100% digital B2B marketplace targeting labs and independent pharmacies [Infomercado, April 2023] directly addresses a structural inefficiency. The outcome is plausible, not merely aspirational, because the wedge is a tangible, launched mobile app with a catalog of over 2,500 products [Infomercado, April 2023]. This positions OpenMed to bypass traditional, multi-layered wholesale channels, offering a path to becoming the category-defining platform for a sector ripe for digital transformation.

Several concrete growth scenarios could propel the company toward this outcome.

Scenario	What happens	Catalyst	Why it's plausible
National Standard in Peru	OpenMed becomes the dominant ordering platform for Peru's estimated 20,000+ independent pharmacies (boticas), capturing a majority of their wholesale purchases.	A strategic partnership with a major pharmaceutical laboratory or a national pharmacy association to integrate ordering and offer exclusive terms.	The company has already launched its core product and frames its mission around empowering independent pharmacies [Infomercado, April 2023]. The market is concentrated and relationship-driven, making a single large partnership a powerful accelerant.
Regional Logistics Expansion	The platform expands beyond digital catalog and ordering to own the last-mile delivery and supply chain financing, becoming an integrated logistics provider.	Securing a funding round specifically earmarked for building a dedicated logistics fleet and warehousing network.	The stated aim to reduce time, capital, and operational work for pharmacies [Infomercado, April 2023] naturally extends into logistics and working capital solutions, a common evolution for successful marketplaces.
Vertical SaaS Pivot	OpenMed layers pharmacy management software (inventory, POS, patient records) on top of its marketplace, locking in customers and increasing revenue per pharmacy.	The accumulation of sufficient transaction data and pharmacy relationships to identify and build the most critical software extensions.	The platform's data is already continuously reviewed and verified by health professionals [OpenMed - made with Wegic], indicating an early focus on data integrity that could support trusted software tools.

The compounding effect for OpenMed would be a classic two-sided network effect combined with a data moat. Each new pharmacy on the platform increases its value to laboratories by offering a broader, more efficient sales channel. Conversely, a richer product catalog and better terms from labs attract more pharmacies. This flywheel, once spinning, creates significant lock-in. Early evidence of this dynamic starting is limited, but the platform's design as an end-to-end solution [Infomercado, April 2023] and its verified product data [OpenMed - made with Wegic] are foundational steps toward creating that trust and dependency.

For a sense of the win's potential size, consider the scale of the market it aims to serve: over 150 million people with chronic diseases in Latin America [Openmed.pe]. While no direct public comparable exists for a Peru-focused pharmaceutical marketplace, regional success stories like Farmalisto (Colombia) illustrate the category's potential. If OpenMed executes on the "National Standard in Peru" scenario, capturing even a single-digit percentage of Peru's multi-billion dollar pharmaceutical distribution market could support a valuation in the hundreds of millions of dollars. This is a scenario-based illustration, not a forecast, but it underscores the material upside if the company can translate its early product launch into dominant market share.

Data Accuracy: YELLOW -- Opportunity framing relies on company-stated market aims and a single regional press article; growth scenarios are extrapolations from the core product claims.

Sources

PUBLIC

1. [Infomercado, April 2023] OpenMed la startup que busca convertirse en el principal Marketplace B2B de la industria farmacéutica | https://www.infomercado.pe/openmed-la-startup-que-busca-convertirse-en-el-principal-marketplace-b2b-de-la-industria-farmaceutica/

2. [OpenMed - made with Wegic] OpenMed | https://openmed.com.vn/

3. [Openmed.pe] Home - OpenMed | https://openmed.com.vn/

4. [Emprendedores de Hoy México] OpenMed | https://openmed.com.vn/

5. [Infomercado] OpenMed la startup que busca convertirse en el principal Marketplace B2B de la industria farmacéutica | https://www.infomercado.pe/openmed-la-startup-que-busca-convertirse-en-el-principal-marketplace-b2b-de-la-industria-farmaceutica/